Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial investigates how well pamiparib and temozolomide work in treating
patients with hereditary leiomyomatosis and renal cell (kidney) cancer. Poly adenosine
diphosphate-ribose polymerase (PARPs) are proteins that help repair DNA mutations. PARP
inhibitors, such as pamiparib, can keep PARP from working, so tumor cells can't repair
themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving pamiparib and temozolomide may
help treat patients with hereditary leiomyomatosis and renal cell cancer.